Lancashire and South Cumbria
Formulary
Formulary
13 Skin
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
13-06-02 Hormone treatment for acne
| Co-Cyprindiol |
|
Formulary
|
| Tablets cyproterone 2mg / ethinylestradiol 35 micrograms CSM advice: VTE risk - see BNF |
 MHRA: Cyproterone acetate with ethinylestradiol (co-cyprindiol): balance of benefits and risks remains positive |
|
Links
- British Association of Dermatologists guideline on safe use of isotretinoin, 2010
LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Aug 2020: Isotretinoin (Roaccutane): reminder of important risks and precautions
- MHRA Drug Safety Update Dec 2014: Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders
- MHRA Drug Safety Update July 2021: Oral retinoid medicines (isotretinoin, alitretinoin, and acitretin): temporary monitoring advice during coronavirus (COVID-19) pandemic
- MHRA Drug Safety Update Oct 2017: Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido
- MHRA update on risk of serious skin reactions (Sept 2010)
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Cyproterone acetate with ethinylestradiol (co-cyprindiol): balance of benefits and risks remains positive
- MHRA: Isotretinoin (Roaccutane▼): introduction of new safety measures, including additional oversight of the initiation of treatment for patients under 18 years of age
- MHRA: Isotretinoin: risk of serious skin reactions
- MHRA: Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
- MHRA: Oral retinoids pregnancy prevention reminder
- MHRA: updated prescribing information regarding risks and benefits (July 2013)
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE new medicine summary: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG198: Acne vulgaris: management
- NICE: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream